Testing for Type 1 Before Symptoms Appear: What a Real-World Pilot Learned

Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing cells in the pancreas. Before symptoms like increased thirst, frequent urination, or fatigue appear, the body produces markers called islet autoantibodies—proteins that signal the immune system is attacking these cells.

A new pilot program tested whether checking for these autoantibodies during routine pediatric care could identify children at risk before they get sick. The goal was not just to prove the concept works, but to understand whether it could actually fit into how clinics operate day-to-day.

Two pediatric clinics participating in the Type 1 Diabetes Exchange Quality Improvement Collaborative spent 18 months developing and testing screening workflows. Over 12 months of active screening, 147 individuals were tested for islet autoantibodies.

The clinics focused on several practical areas: creating clear step-by-step processes for screening and monitoring, educating providers and patients about what the test means, integrating screening into electronic health records, and ensuring screening was available equitably to all families.

When researchers asked care team members what helped the program succeed, several themes emerged. Better communication between doctors, nurses, and other team members made a difference. Streamlining how insurance was handled reduced delays. And improvements to the clinic's electronic health record system made screening easier to organize and track.

These 'facilitators' suggest that presymptomatic screening is not just scientifically possible—it can actually be woven into the way clinics already work, with the right support.

The pilot also identified real obstacles. Clinics had limited staff and resources to dedicate to screening. Some families engaged more readily with the program than others. And insurance coverage for screening was inconsistent, creating barriers for some.

These findings highlight that making early detection routine requires solving not just the medical questions, but the practical ones about staffing, engagement, and access.

Among the 147 people screened, those who tested positive for autoantibodies did not experience diabetic ketoacidosis—a serious complication that can occur when Type 1 diabetes goes undiagnosed. While this is a small pilot and more research is needed, the results suggest that identifying at-risk individuals before symptoms appear may have real benefits.

This work demonstrates that presymptomatic screening can be operationally feasible in routine pediatric care. The next steps involve addressing the identified challenges and expanding what we know about how screening and early monitoring can help families prepare for and manage Type 1 diabetes risk.

Source: BMJ open diabetes research & care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.